Krishnan Nandabalan

Krishnan Nandabalan serves as the President, Chairman, and CEO of AlphaMeld Corporation since April 2017 and is also a Board Member at Invea Therapeutics and BioXcel Therapeutics, Inc. Additionally, Krishnan is the Founder, Chairman, President, and CEO of Invea Therapeutics and holds the position of President, CEO, and Founder at InveniAI LLC. Prior experience includes serving as a Board Member and Co-Founder of BioXcel Corporation and as Vice President of Corporate Development at Genaissance Pharmaceuticals. Krishnan began their career at CuraGen Corporation as Group Leader of Functional Genomics. Education credentials include a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, post-doctoral fellowships at Yale University and the University of Kentucky, and both a BSc and MSc in Microbiology from Tamil Nadu Agricultural University.